Your Best Stock

Takeda Pharmaceutical TAK

US equityMarket cap rank #271Infectious Disease
$18.58
−$0.23 (-1.22%)
Market open · Sep 24, 2:00 pm ET
After hours $18.81 0.00%
Open$18.55
Prev close$18.81
Day range$18.51 – $18.74
Volume1.70M
Market cap$59.34B
P/E (TTM)–
Dividend yield3.22%

Earnings

Average move on report day±3.0%last 15 reports
Closed higher7 of 1547% of the time
Best reaction+2.9%
Worst reaction-7.7%

Stock move on the day after each report

-7.7%2024/Q2-1.5%2024/Q3+2.4%2024/Q4+1.7%2025/Q1+0.4%2025/Q2+2.9%2025/Q3-5.2%2025/Q4-5.0%2026/Q1-3.9%2026/Q2+2.9%2026/Q3+1.3%2026/Q4-2.8%2027/Q1
QuarterReport dateTimingImplied moveActual moveVersus implied
2027/Q229 Oct 2026––––
2027/Q130 Jul 2026–±1.0%-2.82%Bigger than priced
2026/Q413 May 2026–±1.7%+1.34%Within range
2026/Q329 Jan 2026–±1.0%+2.88%Bigger than priced
2026/Q230 Oct 2025–±1.8%-3.92%Bigger than priced
2026/Q130 Jul 2025Pre Market±1.1%-5.03%Bigger than priced
2025/Q48 May 2025Pre Market±0.8%-5.25%Bigger than priced
2025/Q330 Jan 2025Pre Market±0.7%+2.93%Bigger than priced
2025/Q231 Oct 2024–±1.4%+0.36%Within range
2025/Q131 Jul 2024Pre Market–+1.69%–
2024/Q49 May 2024–±1.6%+2.37%Bigger than priced
2024/Q31 Feb 2024Pre Market±0.6%-1.51%Bigger than priced
2024/Q226 Oct 2023–±0.8%-7.72%Bigger than priced
2024/Q127 Jul 2023–±1.0%+1.04%Bigger than priced
2023/Q411 May 2023–±1.1%-4.83%Bigger than priced
2023/Q32 Feb 2023–±1.0%-0.69%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2027/Q1

By business line

  • Gastroenterology (GI)¥386.10B 31.7%
  • Plasma Derived Therapies (PDT)¥283.90B 23.3%
  • Rare Diseases¥206.00B 16.9%
  • Oncology¥165.60B 13.6%
  • Neuroscience¥113.60B 9.3%
  • Other¥50.70B 4.2%
  • Vaccines¥14.00B 1.1%

Latest reported quarter: Q1, ended Jun 2026 · reported in JPY

Revenue¥1.22T+10.2% YoY
Operating profit¥201.42B+9.1% YoY
Net profit¥113.26B-8.9% YoY
Diluted EPS¥35.27-9.8% YoY
Free cash flow¥127.60M-40.8% YoY
Operating cash flow¥127.60M

Revenue, last 8 quarters

¥1.2TSep '24¥1.1TDec '24¥1.1TMar '25¥1.1TJun '25¥1.1TSep '25¥1.2TDec '25¥1.1TMar '26¥1.2TJun '26

Net profit, last 8 quarters

¥92.1BSep '24¥23.8BDec '24¥-103.1BMar '25¥124.3BJun '25¥-11.7BSep '25¥103.7BDec '25¥-368.4BMar '26¥113.3BJun '26

Profitability & balance sheet

Gross margin65.5%
Operating margin10.4%
Net margin-3.5%
Return on equity-2.3%
Return on assets-1.1%
Return on invested capital-0.7%
Current ratio1.14
Liabilities / assets51.7%
Cash & investments¥527.58B
Total debt¥4.94T
Net cash (debt)-¥4.41T
Free cash flow / sales13.6%
Scroll to Top